Scholarly Articles for HemoHIM

  • Published: 17 Mar 2021
  • Conclusion: The present study was conducted to evaluate the antiamnesic activity of HemoHIM in a scopolamine-induced memory impairment murine model. HemoHIM administration effectively ameliorated cognitive deficits determined using PAT, NORT, and Y-maze behavioral tests. HemoHIM effectively inhibited AchE activity. Furthermore, HemoHIM may attenuate memory impairment by activating the BDNF-ERK-CREB pathway. These results indicate that HemoHIM can be used pharmaceutically for the treatment or prevention of amnesia and dementia and can be used as a supplement to improve dementia symptoms.
  • Acknowledgments: This research was supported by a grant from Kolmar BNH, Korea.

  • Date of Acceptance: 10 March 2021
  • Results and Discussion:
    SOD is responsible for protecting the toxic effects of superoxide radical by catalyzing its dismutation reactions and CAT plays an important role in removal of hydrogen peroxide and preventing from the oxidative stress related damage. Compared with the APAP group, the increased expression of SOD and CAT were founded in HemoHIM groups, in agreement with other studies[28]. Therefore, HemoHIM seems to be effective in oxidative liver injury by APAP through this pathway.

    The significant decrease in COX-2 expression after HemoHIM treatment suggested that HemoHIM can significantly inhibit activity and generation of inflammatory agents. The reduction in inflammatory response by HemoHIM was also confirmed in vivo.

    HemoHIM significantly inhibited APAP induced hepatic injury by promoting antioxidant activity though the Nrf-2/HO-1 signaling pathway and attenuating pro-inflammatory cytokines as well as, destruction of hepatocytes. Thus, HemoHIM may be a potent hepatoprotective agent.
  • Acknowledgments: This research was supported by a grant from Kolmar BNH Co., Ltd., Korea

  • Published online: 04 Apr 2021
  • Results: HemoHIM significantly restored reduced antioxidant enzymes (SOD, CAT, Txn, GPx, GSr, and GCLC in HemoHIM 500 μg/mL) compared to the citrinin group in L6 cells. In vivo, HemoHIM significantly improved the latency time (FST; 279.88 ± 50.32 sec, rotarod test; 552.35 ± 23.50 sec in HemoHIM 500 mg/kg). Moreover, the FST-induced reduction in glucose and glutathione significantly increased by 3-fold (HemoHIM 500 mg/kg) and increase in LDH and MDA were significantly inhibited by 1.6, 2.1-fold in the HemoHIM 500 mg/kg compared to the control group.
  • Funding: This research was supported by a grant from Kolmar BNH Co., Ltd., Korea.

  • Published online: 2021 Feb 15
  • HemoHIM is a prescription composed of three herbs with various biological and immunological activities. HemoHIM inhibits the continuous down-regulation of Th1 immune responses after radiation by regulating the IL-12 p70/pSTAT4 signaling pathway (Park et al., 2012). This prescription has also been shown to protect hematopoietic stem cells and speeds up the recovery of immune cells (Park et al., 2014).
  • Funding: This work was supported by the National Natural Science Foundation of China (No. 11675027, 12075035).

Protective effects of a standardized extract (HemoHIM) using indomethacin- and ethanol/HCl-induced gastric mucosal injury models

  • Published online: 20 Aug 2019
  • Discussion and conclusions: Based on the results, HemoHIM is potential candidate for the treatment of gastritis and gastric ulcers.
  • Funding: This research was supported by a grant from Kolmar BNH Co., Ltd., Korea.

Immunomodulatory and Antidiabetic Effects of a New Herbal Preparation (HemoHIM) on Streptozotocin-Induced Diabetic Mice

  • Published 18 Jun 2014
  • In conclusion, HemoHIM improved the symptom of STZ-induced diabetic. The evidence of these characteristics of HemoHIM includes (1) restoration from destroyed β-cells by STZ; (2) increase in blood insulin level; (3) decrease in blood glucose level by increased insulin; (4) protection of body and organs weight from disruption by STZ; (5) inhibitition of immunological changes by STZ. On the basis of the results described herein, we suggest that HemoHIM has antidiabetic potential against increase in blood glucose levels and even immune system disruption.
  • Acknowledgments: This study was supported by a Grant of the Traditional Korean Medicine R&D Project, Ministry of Health & Welfare, Republic of Korea (HI12C1893), and Suncheon Research Center for Natural Medicines, Republic of Korea.

Post a Comment